Logo image of QGEN

QIAGEN N.V. (QGEN) Stock Fundamental Analysis

NYSE:QGEN - New York Stock Exchange, Inc. - NL0015002CX3 - Common Stock - Currency: USD

48.23  +0.1 (+0.21%)

Fundamental Rating

6

QGEN gets a fundamental rating of 6 out of 10. The analysis compared the fundamentals against 56 industry peers in the Life Sciences Tools & Services industry. Both the health and profitability get an excellent rating, making QGEN a very profitable company, without any liquidiy or solvency issues. QGEN is not valued too expensively and it also shows a decent growth rate. This makes QGEN very considerable for quality investing!


Dividend Valuation Growth Profitability Health

7

1. Profitability

1.1 Basic Checks

QGEN had positive earnings in the past year.
QGEN had a positive operating cash flow in the past year.
Each year in the past 5 years QGEN has been profitable.
QGEN had a positive operating cash flow in each of the past 5 years.
QGEN Yearly Net Income VS EBIT VS OCF VS FCFQGEN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M 400M 600M

1.2 Ratios

With a decent Return On Assets value of 1.47%, QGEN is doing good in the industry, outperforming 73.21% of the companies in the same industry.
QGEN has a better Return On Equity (2.34%) than 71.43% of its industry peers.
QGEN has a better Return On Invested Capital (7.14%) than 78.57% of its industry peers.
Measured over the past 3 years, the Average Return On Invested Capital for QGEN is significantly below the industry average of 13.15%.
Industry RankSector Rank
ROA 1.47%
ROE 2.34%
ROIC 7.14%
ROA(3y)4.59%
ROA(5y)5.65%
ROE(3y)7.84%
ROE(5y)10.58%
ROIC(3y)7.25%
ROIC(5y)7.96%
QGEN Yearly ROA, ROE, ROICQGEN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 5 10 15

1.3 Margins

QGEN has a better Profit Margin (4.23%) than 73.21% of its industry peers.
In the last couple of years the Profit Margin of QGEN has declined.
QGEN has a Operating Margin of 25.02%. This is amongst the best in the industry. QGEN outperforms 94.64% of its industry peers.
In the last couple of years the Operating Margin of QGEN has grown nicely.
QGEN has a better Gross Margin (63.82%) than 91.07% of its industry peers.
QGEN's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 25.02%
PM (TTM) 4.23%
GM 63.82%
OM growth 3Y-5.04%
OM growth 5Y4.09%
PM growth 3Y-42.96%
PM growth 5YN/A
GM growth 3Y-0.32%
GM growth 5Y-0.63%
QGEN Yearly Profit, Operating, Gross MarginsQGEN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 40 60

8

2. Health

2.1 Basic Checks

With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), QGEN is destroying value.
QGEN has less shares outstanding than it did 1 year ago.
QGEN has less shares outstanding than it did 5 years ago.
Compared to 1 year ago, QGEN has an improved debt to assets ratio.
QGEN Yearly Shares OutstandingQGEN Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M
QGEN Yearly Total Debt VS Total AssetsQGEN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2B 4B 6B

2.2 Solvency

An Altman-Z score of 4.48 indicates that QGEN is not in any danger for bankruptcy at the moment.
QGEN has a better Altman-Z score (4.48) than 80.36% of its industry peers.
The Debt to FCF ratio of QGEN is 2.77, which is a good value as it means it would take QGEN, 2.77 years of fcf income to pay off all of its debts.
QGEN has a Debt to FCF ratio of 2.77. This is amongst the best in the industry. QGEN outperforms 80.36% of its industry peers.
QGEN has a Debt/Equity ratio of 0.38. This is a healthy value indicating a solid balance between debt and equity.
Looking at the Debt to Equity ratio, with a value of 0.38, QGEN is in line with its industry, outperforming 48.21% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.38
Debt/FCF 2.77
Altman-Z 4.48
ROIC/WACC0.97
WACC7.33%
QGEN Yearly LT Debt VS Equity VS FCFQGEN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 1B 2B 3B

2.3 Liquidity

QGEN has a Current Ratio of 3.61. This indicates that QGEN is financially healthy and has no problem in meeting its short term obligations.
With a Current ratio value of 3.61, QGEN perfoms like the industry average, outperforming 57.14% of the companies in the same industry.
A Quick Ratio of 3.09 indicates that QGEN has no problem at all paying its short term obligations.
QGEN has a Quick ratio of 3.09. This is comparable to the rest of the industry: QGEN outperforms 58.93% of its industry peers.
Industry RankSector Rank
Current Ratio 3.61
Quick Ratio 3.09
QGEN Yearly Current Assets VS Current LiabilitesQGEN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B 2B

5

3. Growth

3.1 Past

The Earnings Per Share has grown by an nice 11.95% over the past year.
QGEN shows quite a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 8.25% yearly.
QGEN shows a small growth in Revenue. In the last year, the Revenue has grown by 0.66%.
QGEN shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 5.32% yearly.
EPS 1Y (TTM)11.95%
EPS 3Y-6.88%
EPS 5Y8.25%
EPS Q2Q%19.57%
Revenue 1Y (TTM)0.66%
Revenue growth 3Y-4.22%
Revenue growth 5Y5.32%
Sales Q2Q%5.37%

3.2 Future

The Earnings Per Share is expected to grow by 9.10% on average over the next years. This is quite good.
The Revenue is expected to grow by 7.82% on average over the next years.
EPS Next Y8.56%
EPS Next 2Y8.59%
EPS Next 3Y8.95%
EPS Next 5Y9.1%
Revenue Next Year4.26%
Revenue Next 2Y4.98%
Revenue Next 3Y5.58%
Revenue Next 5Y7.82%

3.3 Evolution

When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
QGEN Yearly Revenue VS EstimatesQGEN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 1B 2B 3B
QGEN Yearly EPS VS EstimatesQGEN Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 1 2 3

6

4. Valuation

4.1 Price/Earnings Ratio

With a Price/Earnings ratio of 20.97, QGEN is valued on the expensive side.
Based on the Price/Earnings ratio, QGEN is valued cheaply inside the industry as 80.36% of the companies are valued more expensively.
The average S&P500 Price/Earnings ratio is at 27.41. QGEN is valued slightly cheaper when compared to this.
Based on the Price/Forward Earnings ratio of 18.54, the valuation of QGEN can be described as rather expensive.
Based on the Price/Forward Earnings ratio, QGEN is valued cheaply inside the industry as 82.14% of the companies are valued more expensively.
The average S&P500 Price/Forward Earnings ratio is at 35.19. QGEN is valued slightly cheaper when compared to this.
Industry RankSector Rank
PE 20.97
Fwd PE 18.54
QGEN Price Earnings VS Forward Price EarningsQGEN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60

4.2 Price Multiples

Based on the Enterprise Value to EBITDA ratio, QGEN is valued cheaper than 87.50% of the companies in the same industry.
Based on the Price/Free Cash Flow ratio, QGEN is valued cheaper than 83.93% of the companies in the same industry.
Industry RankSector Rank
P/FCF 20.79
EV/EBITDA 14.57
QGEN Per share dataQGEN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 5 10 15

4.3 Compensation for Growth

The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates QGEN does not grow enough to justify the current Price/Earnings ratio.
QGEN has a very decent profitability rating, which may justify a higher PE ratio.
PEG (NY)2.45
PEG (5Y)2.54
EPS Next 2Y8.59%
EPS Next 3Y8.95%

2

5. Dividend

5.1 Amount

With a yearly dividend of 0.51%, QGEN is not a good candidate for dividend investing.
Compared to an average industry Dividend Yield of 0.50, QGEN pays a better dividend. On top of this QGEN pays more dividend than 92.86% of the companies listed in the same industry.
Compared to an average S&P500 Dividend Yield of 2.35, QGEN's dividend is way lower than the S&P500 average.
Industry RankSector Rank
Dividend Yield 0.51%

5.2 History

QGEN is new to the dividend game and has less than 3 years of track record.
Dividend Growth(5Y)N/A
Div Incr Years0
Div Non Decr Years0
QGEN Yearly Dividends per shareQGEN Yearly Dividends per shareYearly Dividends per share 2024 2025 0.2 0.4 0.6 0.8 1

5.3 Sustainability

DPN/A
EPS Next 2Y8.59%
EPS Next 3Y8.95%
QGEN Yearly Income VS Free CF VS DividendQGEN Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M 400M

QIAGEN N.V.

NYSE:QGEN (7/14/2025, 2:26:40 PM)

48.23

+0.1 (+0.21%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)05-07 2025-05-07/amc
Earnings (Next)08-05 2025-08-05/amc
Inst Owners86.78%
Inst Owner Change0%
Ins Owners0.44%
Ins Owner ChangeN/A
Market Cap10.44B
Analysts76.67
Price Target50.38 (4.46%)
Short Float %2.65%
Short Ratio4.04
Dividend
Industry RankSector Rank
Dividend Yield 0.51%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-Date07-02 2025-07-02 (0.25)
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-0.23%
Min EPS beat(2)-3.85%
Max EPS beat(2)3.38%
EPS beat(4)3
Avg EPS beat(4)1.13%
Min EPS beat(4)-3.85%
Max EPS beat(4)3.38%
EPS beat(8)5
Avg EPS beat(8)1.25%
EPS beat(12)9
Avg EPS beat(12)4.32%
EPS beat(16)13
Avg EPS beat(16)5.2%
Revenue beat(2)0
Avg Revenue beat(2)-0.97%
Min Revenue beat(2)-1.92%
Max Revenue beat(2)-0.02%
Revenue beat(4)0
Avg Revenue beat(4)-1.29%
Min Revenue beat(4)-1.92%
Max Revenue beat(4)-0.02%
Revenue beat(8)0
Avg Revenue beat(8)-1.08%
Revenue beat(12)4
Avg Revenue beat(12)-0.09%
Revenue beat(16)7
Avg Revenue beat(16)0.75%
PT rev (1m)-0.35%
PT rev (3m)-0.73%
EPS NQ rev (1m)0%
EPS NQ rev (3m)1.51%
EPS NY rev (1m)0.46%
EPS NY rev (3m)3.01%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0.62%
Revenue NY rev (1m)0.14%
Revenue NY rev (3m)1.54%
Valuation
Industry RankSector Rank
PE 20.97
Fwd PE 18.54
P/S 5.28
P/FCF 20.79
P/OCF 15.51
P/B 2.93
P/tB 12.46
EV/EBITDA 14.57
EPS(TTM)2.3
EY4.77%
EPS(NY)2.6
Fwd EY5.39%
FCF(TTM)2.32
FCFY4.81%
OCF(TTM)3.11
OCFY6.45%
SpS9.13
BVpS16.47
TBVpS3.87
PEG (NY)2.45
PEG (5Y)2.54
Profitability
Industry RankSector Rank
ROA 1.47%
ROE 2.34%
ROCE 9.62%
ROIC 7.14%
ROICexc 9.2%
ROICexgc 29.06%
OM 25.02%
PM (TTM) 4.23%
GM 63.82%
FCFM 25.39%
ROA(3y)4.59%
ROA(5y)5.65%
ROE(3y)7.84%
ROE(5y)10.58%
ROIC(3y)7.25%
ROIC(5y)7.96%
ROICexc(3y)9.42%
ROICexc(5y)10.13%
ROICexgc(3y)34.6%
ROICexgc(5y)42.77%
ROCE(3y)9.77%
ROCE(5y)10.73%
ROICexcg growth 3Y-31.24%
ROICexcg growth 5Y-2.41%
ROICexc growth 3Y-13.09%
ROICexc growth 5Y6.48%
OM growth 3Y-5.04%
OM growth 5Y4.09%
PM growth 3Y-42.96%
PM growth 5YN/A
GM growth 3Y-0.32%
GM growth 5Y-0.63%
F-Score7
Asset Turnover0.35
Health
Industry RankSector Rank
Debt/Equity 0.38
Debt/FCF 2.77
Debt/EBITDA 1.92
Cap/Depr 84.24%
Cap/Sales 8.66%
Interest Coverage 20.47
Cash Conversion 96.47%
Profit Quality 600.91%
Current Ratio 3.61
Quick Ratio 3.09
Altman-Z 4.48
F-Score7
WACC7.33%
ROIC/WACC0.97
Cap/Depr(3y)78.4%
Cap/Depr(5y)95.94%
Cap/Sales(3y)7.97%
Cap/Sales(5y)9.87%
Profit Quality(3y)273.85%
Profit Quality(5y)189.74%
High Growth Momentum
Growth
EPS 1Y (TTM)11.95%
EPS 3Y-6.88%
EPS 5Y8.25%
EPS Q2Q%19.57%
EPS Next Y8.56%
EPS Next 2Y8.59%
EPS Next 3Y8.95%
EPS Next 5Y9.1%
Revenue 1Y (TTM)0.66%
Revenue growth 3Y-4.22%
Revenue growth 5Y5.32%
Sales Q2Q%5.37%
Revenue Next Year4.26%
Revenue Next 2Y4.98%
Revenue Next 3Y5.58%
Revenue Next 5Y7.82%
EBIT growth 1Y11.16%
EBIT growth 3Y-9.05%
EBIT growth 5Y9.63%
EBIT Next Year58.48%
EBIT Next 3Y22.89%
EBIT Next 5Y16.26%
FCF growth 1Y69.33%
FCF growth 3Y5.12%
FCF growth 5Y55.1%
OCF growth 1Y46.6%
OCF growth 3Y1.77%
OCF growth 5Y15.28%